The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update

The international, phase III, multi-centre AZA-001 trial demonstrated azacitidine (AZA) is the first treatment to significantly extend overall survival (OS) in higher risk myelodysplastic syndromes (MDS) patients (Fenaux (2007) Blood 110 817). The current treatment paradigm, which is based on a rela...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Silverman, LR, Fenaux, P, Mufti, GJ, Santini, V, Hellström-Lindberg, E, Gattermann, N, Sanz, G, List, AF, Gore, SD, Seymour, JF, Backstrom, J, McKenzie, D, Beach, CL
Materialtyp: Artigo
Språk:Inglês
Publicerad: Cancer Intelligence 2008
Ämnen:
Short Communications
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3234059/
https://ncbi.nlm.nih.gov/pubmed/22275990
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3332/ecancer.2008.118
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk